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Abstract 
Mesenteric panniculitis (MP) is a rare dis-
ease occasionally complicated with lymphoma.
A 55-year old female presented with MP accom-
panied by malignant lymphoma. This patient
was first treated for follicular lymphoma and
subsequently for panniculitis. After 6 courses
of  R-CHOP  chemotherapy,  the  treatment
response was partial. An additional course of
salvage  chemotherapy  led  to  a  complete
response.  Since  the  mesenteric  mass  pro-
gressed simultaneously with the regression of
other lymphoma lesions, we performed a biop-
sy of the mesenteric mass and pathologically
confirmed  an  MP  lesion  without  lymphoma.
Subsequent high-dose chemotherapy led to CR
and  the  MP  lesion  remained  stable.  In  the
present case, MP progressed with chemothera-
py. We concluded that mesenteric lesions sus-
pected of progressing or recurring should be
diagnosed pathologically even if asymptomatic. 
Introduction
An extensive involvement of mesenteric fat
tissue of the small bowel with chronic non-spe-
cific  inflammatory  disease,  first  reported  by
Jura et al.in 1924
1 was described, detailed, and
named  as  mesenteric  panniculitis  (MP)  by
Ogden et al. in 1960.
2 MP is always discussed
with pathological findings concerning its etiol-
ogy  and  3  components  of  histology,  fibrosis,
chronic inflammation, and fat necrosis, sug-
gesting various mechanisms of disease (called
sclerotic  mesenteritis,  mesenteric  panniculi-
tis, and mesenteric lipodystrophy, respective-
ly).
3 Histologically, MP lesion is characterized
by the infiltration of mesenteric fat tissue by
inflammatory cells, mainly consisting of lym-
phocytes and plasmacytes, along with a mix-
ture of fat necrosis and fibrosis.
3 Although the
diagnosis  of  MP  before  biopsy  is  primarily
based  on  guesswork,  computed  tomography
(CT) findings are helpful for cases in which
mesentery biopsy is problematic.
4 The clinical
course of MP is usually benign, and sponta-
neous remission is quite common without spe-
cific treatment.
5
The  pathogenesis  of  MP  remains  obscure
and  many  associated  diseases  are  known,
including mechanical stimulation such as sur-
gery or trauma, infections, vascular diseases,
and malignant and non-malignant neoplasms.
5
The occurrence rate of lymphoma as an under-
lying disease is 15% or more, and no malignant
involvement of the mesentery was diagnosed
in almost all cases.
5 In a case series of  MP
accompanied  with  malignant  lymphoma,
Kipfer et al. (8 cases) suggested that mesen-
teritis was a non-specific response to underly-
ing lymphoma.
5 Other reports introduced MP
incidence during the clinical follow-up course
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Figure 1. Imaging and pathologic evaluation of mesenteric panniculitis. During treat-
ment and before SCT, we evaluated the clinical course of the mesenteric mass by CT (A)
and 18F-FDG-PET (B). (A) Clinical course of mesenteric lesion evaluated by CT imag-
ing. Mesenteric hypertrophy before treatment reduced during chemotherapy (i), after sal-
vage chemotherapy (ii), and before PBSCT (iii). Arrows indicate hypertrophic mesenteri-
um. (B) Clinical course of mesenteric lesion evaluated by FDG-PET. An accumulation
positioned at the mesenterium detected by FDG-PET (i) was more intensified after sal-
vage chemotherapy (ii) and did not improve before PBSCT (iii). Arrows indicate an
increased accumulation in accordance with the enlarged mesenterium. (C) Pathological
findings of biopsied mesenteric mass. Fatty necrosis surrounded by foamy macrophages
and  reactive  lymph  adenopathy  was  characteristic  of  the  mesenterium.
Immunohistological staining failed to detect CD20, CD10, CD79a, and bcl-2, with no
indications of malignant lymphoma:  (i) H-E stain (x 400), (ii) H-E stain (x 1000).[Hematology Reviews 2009; 1:e17] [page 95]
of  lymphoma.  Ogden  (2  cases)
6 and  Perez-
Ferriols (1 case)
7 both reported on the associa-
tion of these 2 diseases. 
Case Report
A 55-year old woman presented with right
cervical lymph node swelling in July, 2004, fol-
lowed by inguinal lymph node swelling a few
weeks later. She was admitted to our hospital in
August, 2004. The results of the blood and bone
marrow examinations performed at that time
are shown in Table 1. A lymph node biopsy of
the  inguinal  area  revealed  grade  2  follicular
lymphoma. CT images of her neck, thorax and
abdomen, and FDG-PET revealed stage IV dis-
ease. She was diagnosed as having stage IV
lymphoma with femoral bone involvement, as
confirmed by femoral MRI. Her follicular lym-
phoma international prognostic index (FLIPI)
was  intermediate  (stage  and  lymph-node
lesions). IgH-BCL rearrangement (FISH) was
detected in her lymph nodes and bone marrow
cells,  although  neither  morphological  abnor-
mality nor apparent involvement of lymphoma
cells were revealed. We did not examine her for
IgH-BCL rearrangement of peripheral blood. B
symptoms  were  absent;  however,  since  she
complained of bone pain and it was progres-
sive, we decided to treat her with chemothera-
py. R-CHOP chemotherapy consisted of ritux-
imab  (375  mg/m
2,  day  0),  cyclophosphamide
(750 mg/m
2, day 1), doxorubicin (50 mg/m
2, day
1), vincristine (1.4 mg/m
2, day 1), and pred-
nisolone  (100  mg/kg  body  weight,  day  1-5),
injected tri-weekly until 6 courses were com-
pleted.  At  this  point  only  a  partial  response
(PR) was observed through objective radiologi-
cal evaluations (for nodal masses FDG-PET was
negative  and  more  than  50%  regression  was
observed on CT). After R-CHOP, 2 courses at a 3-
week interval of the ACES regimen (cytarabine
2,000 mg/m
2 day 5, carboplatin 100 mg/m
2 day 1-
4,  etoposide  80  mg/m
2 days  1-4,  methylpred-
nisolone 500 mg/body days 1-5) were used as
salvage chemotherapy, after which her disease
was considered to be in CR (IgH-BCL rearrange-
ment  in  her  lymph  nodes  and  bone  marrow
became negative). At the same time, a contrast-
enhanced  peritoneal  mass  appeared  on  CT
imaging (Figure 1A) and FDG-PET (Figure 1B).
We identified the pathological etiology of the
peritoneal lesion proceeding to the peripheral
blood stem cell transplantation (PBSCT) by CT-
guided biopsy, which revealed mesenteric pan-
niculitis (MP) not concomitant with the lym-
phoma lesion (Figure 1C). Her MP did not pro-
duce symptoms through her treatment course.
However,  the  bone  lesion  recurred  in  June,
2005, when she received PBSCT. She has main-
tained CR with no progression of the MP mass
for more than three years. 
Discussion
Mesenteric  panniculitis  is  a  lipodystrophy
characterized  by  non-specific  inflammatory
disease first reported by Ogden et al.
2 Emory et
al. reviewed 84 cases of MP pathologically and
documented that a mixed histology of 3 compo-
nents (fibrosis, chronic inflammation, and fat
necrosis) existed in the lesions, which could
be classified according to the dominant patho-
logical changes, i.e. mesenteric lipodystrophy
(ML) type, mesenteric panniculitis (MP) type,
and  sclerosing  mesenteritis  (SM)  type.
However, not all cases can be definitively cate-
gorized in these 3 subtypes because the histo-
logically dominant subtype is often too varied
to define as ML, MP, or SM, respectively.
3 Due
to this pathological variation and the various
underlying diseases of MP, the etiology of this
disease  is  thought  to  be  a  single  pathology
with various causes including immunological
reactions,  malignancies,  infection,  physical
stimulation, or traumatic disorders. 
Past retrospective analysis reported that, in
general,  MP  occurs  in  patients  in  their  60s
(median age of occurrence), has slightly high-
er  incidence  in  men,  is  accompanied  by
abdominal pain, and is often associated with
malignant lymphoma.
8,9 Generally, isolated MP
does  not  need  to  be  treated.
4 Kipfer  et  al.
reported that 8 among 53 reviewed cases of MP
with malignant lymphoma led to complications
related to MP.
5 They could find no pathological
involvement of lymphoma in the panniculitis
lesion in any case. In 3 of the 8 cases, MP
existed  with  malignant  lymphoma  concomi-
tantly. In 2 other patients, the lymphoma lesion
was found two or three months later. Another 3
patients were diagnosed as having malignant
lymphoma occurring in a different area from
the MP lesion. These findings suggest that MP
can precede or proceed to lymphoma. However,
no  panniculitis  has  been  revealed  in  lym-
phoma lesions by biopsy, and no obvious asso-
ciation  has  been  reported  until  now.  In  our
case,  the  mesenteric  lesion  progressed  and
was  detected  by  FDG-PET  imaging  during
Case Report
Table 1. Laboratory data on admission. The profile of the peripheral blood cell count was
within the normal range.  Biochemical data showed a normal LDH level and no organ
disorders. Cytogram of bone marrow revealed no obvious morphological changes and the
involvement of lymphoma cells was not detected.  
Component of blood cell
White blood cells  9100 /ʼL (3500~9100)
Granulocytes  69% (32~79)
Eosinophils 1% (0~6)
Basaophils 2% (0~2)
Monocytes 3% (0~8)
Lymphocytes 25% (18~59)
Red blood cells  415x10
4 /ʼL (376~500) 
Hemoglobin  12.6 g/dL 11.3~15.2) 
Hematocrit 37.4% (33.4~44.9) 
Platelets  23.1x10
4 /ʼL(13.0~36.9) 
Biochemistry
Total protein  7.7 g/dL (6.7~8.3) 
Albumin  4.6 g/dL  (4.0~5.0) 
Total billirubin  0.4 mg/dL (0.3~1.2)
Glutamic pyruvic transaminase  19 IU/L (5~40)
Lactate dehydrogenase  195 IU/L (115~245)
Alkaline phosphatase  259 IU/L (115~359)
Blood urea nitrogen  15.9 mg/dL (8.0~22.0)
Creatinine  0.6 mg/dL (0.47~0.79)
Urine acid  3.8 mg/dL (2.5~7.0)
Natrium  142 mEq/L (136~147)
Potassium  4.1 mEq/L (3.6~5.0)
Chloride 106 mEq/L (98~109)
Coagulation
Prothrombin time  97% (70~130)
Activated partial thromboplastin time 28.5 sec (24.3~36.0)
International normalized ratio  1.02 (0.85~1.15)
Fibrinogen  274 mg/dL (150~400)
Bone marrow 
Number of nuclear cells  9.4 x10
4 /ʼL (10~20)
Megakaryocytes  43.8x10
4 /ʼL (50~150)
Myeloid/erythroid ratio 2.36 (2~4)
Blasts  0.2% (1.0~1.5)
Promyelocytes  0.6% (2.0~6.5)[page 96] [Hematology Reviews 2009; 1:e17]
chemotherapy, which reduced to remission the
lymphoma lesions (lymph nodes and femoral
bone  head).  This  discrepant  course  made  it
problematic for physicians to decide on a treat-
ment plan. If we had regarded the mesenteric
mass in our patient as refractory lymphoma,
we would have had to administer a salvage reg-
imen. If the mesenteric mass had been benign,
we could have continued the existing regimen.
A biopsy confirmed the remission of her lym-
phoma and resolved this problem. Autologous
PBSCT  brought  about  a  durable  CR  in  the
patient.  The  MP  lesion  regressed  after  the
planned  treatments,  with  no  recurrence  for
three years. Therefore, we recognized that her
MP  was  chemotherapy-related  panniculitis,
since  panniculitis  is  thought  to  be  brought
about by physical or chemical stimulation.
5
Although  FDG-PET  was  an  effective  and
powerful tool for the staging, localization, and
response assessment of malignant lymphoma,
the  differential  diagnosis  for  lymphoma
lesions  with  physiological  accumulation  or
inflammatory change is sometimes difficult.
10,11
Though FDG-PET/CT fusion imaging is more
efficient for diagnosis of the active lymphoma
lesion,
11 a pathological diagnosis via biopsy is
essential for cases in which a false positive is
suspected. Zissin et al.reviewed 19 oncological
patients with MP
12 and reported that FDG-PET
had high specificity (100%) among 11 FDG-
PET-negative subjects and 88% sensitivity (7
out of 8 subjects). We concluded that mesen-
teric lesions suspected of progressing or recur-
ring with positive uptake with FDG-PET should
be diagnosed pathologically even if asympto-
matic. 
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